Since his second term began, President Trump has unveiled a range of actions aimed at lowering prescription drug costs — letters to 17 drugmakers asking for voluntary price cuts, private meetings with more than a dozen pharmaceutical CEOs, a pledge of “most favored nation” pricing for Medicaid, and the launch of TrumpRx, a website offering discounted cash prices. The administration also said it would speed approval of biosimilars, the near-generic versions of expensive biologic medicines.
But the practical effect of many of these moves has been narrow. Several announced deals are limited in scope, often overlap with existing coupons or discount programs, and sometimes require patients to know where and how to access the savings. Critics and pricing experts describe many of the White House’s agreements as publicity-driven, opaque, and difficult to enforce. Even as the administration touted discounts, data show continued list-price increases for many brand drugs: tracking firms reported nearly 1,000 brand-name price hikes in January 2026 alone, and companies such as Pfizer raised list prices on dozens of drugs early in the year.
The most consequential effort to lower drug spending so far has been the continuation of a Biden-era Medicare negotiation program. Negotiated discounts for an initial group of high-cost medicines took effect on Jan. 1, with some price cuts exceeding 50%. Those savings helped enable a $2,000 annual cap on out-of-pocket Part D spending starting in 2025. Additional rounds of negotiations finalized more drugs in 2024 and 2025, and the full set of about 40 negotiated prices is projected to save Medicare more than $20 billion a year. Industry lobbying has tried to limit the program’s reach, including proposals to exempt rare-disease treatments, but experts say government negotiation is a historic shift that has not halted pharmaceutical innovation.
Yet those negotiated savings mainly benefit Medicare enrollees. The Trump administration’s other measures — company-by-company deals, TrumpRx discounts, and promises to accelerate biosimilars — tend to help narrower groups: uninsured or cash-paying patients who can find and use the portal’s offers, or people eligible for particular company coupons. Many TrumpRx listings duplicate discounts already available through private platforms like GoodRx. In practice, some branded drugs on TrumpRx remain far more expensive than generic alternatives available elsewhere.
Examples highlight the limitations. A branded cholesterol drug listed on TrumpRx at about $128 (advertised as 50% off) competes with generic versions that cost roughly $17 at discount pharmacies. Some discounted branded drugs are older medicines or are useful only as part of multi‑drug regimens, reducing the real-world value of a single reduced price. Monthly prices for certain arthritis or HIV drugs fell substantially on the portal but stayed unaffordable for many cash-paying patients. TrumpRx has also listed biologic products such as Humira at much lower prices than earlier list levels, even though Humira lost U.S. patent protection in 2023 and biosimilars are already available — some of which appear on the portal at much lower per-dose prices than branded versions.
A few headline-making deals do yield meaningful savings for specific consumers. Fertility drugs from EMD Serono were offered at sharply lower prices with coupons, potentially cutting the drug portion of an IVF cycle, although IVF’s total cost — often $15,000–$25,000 for multiple cycles — remains high. In return for price reductions, companies sometimes secured other concessions, such as lifted tariffs or expedited regulatory review. Weight‑loss GLP-1 drugs produced notable price drops in some announced deals: Wegovy was listed as low as about $199 per monthly pen and other GLP-1s appeared for a few hundred dollars per month. Still, insurers commonly cover these drugs only for diabetes, not for weight loss, and patent strategies could keep cheaper generics and biosimilars off the U.S. market for years. Patent experts say complex patent thickets on many GLP‑1 products could delay generics until the late 2030s.
Speeding FDA approval of biosimilars could help expand lower-cost options, but regulatory timelines are often not the main bottleneck. Legal and patent barriers, settlements, and market maneuvers frequently delay generics and biosimilars long after regulatory approval is granted. One notable example: a generic approved years ago that still cannot reach the market because of lingering legal and commercial obstacles.
Other proposed fixes — for instance, requiring drugmakers to rebate Medicare if they charge the U.S. more than other countries for certain single-source drugs — remain in rulemaking and would primarily assist Medicare beneficiaries rather than the broader population.
For uninsured or cash-paying shoppers who are willing and able to compare prices across many programs and use coupons, genuine bargains exist. But those savings are scattered across different portals, company coupons, and pharmacy discount programs, and finding the lowest price often requires persistent comparison shopping. For many patients — especially those with insurance gaps, high cost-sharing, or limited means — the administration’s measures may offer some relief in particular cases but do not amount to a sweeping overhaul of how drug prices are set or why U.S. prices remain substantially higher than in other nations.
In short, a mix of targeted discounts and publicity-driven deals has produced meaningful savings for some people, while broader structural changes — especially Medicare negotiation and patent reform affecting biosimilars — will determine whether U.S. drug spending falls more substantially over time.